Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHEK1 | O14757 | 2/20 | 0.51 |
| ▸ | RET | P07949 | 4/20 | 0.38 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.37 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.35 |
| ▸ | MET | P08581 | 1/20 | 0.32 |
| ▸ | PIK3CD | O00329 | 4/20 | 0.32 |
| ▸ | PIK3CA | P42336 | 4/20 | 0.32 |
| ▸ | PIK3CB | P42338 | 4/20 | 0.32 |
| ▸ | PIK3CG | P48736 | 4/20 | 0.32 |
| ▸ | PRKDC | P78527 | 4/20 | 0.32 |
| ▸ | LRRK2 | Q5S007 | 3/20 | 0.32 |
| ▸ | PI4KA | P42356 | 3/20 | 0.32 |
| ▸ | PI4K2B | Q8TCG2 | 3/20 | 0.32 |
| ▸ | PI4K2A | Q9BTU6 | 3/20 | 0.32 |
| ▸ | PI4KB | Q9UBF8 | 3/20 | 0.32 |
| ▸ | XDH | P47989 | 2/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | DRD3 | P35462 | 1/20 | 0.32 |
| ▸ | ERAP1 | Q9NZ08 | 1/20 | 0.32 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL397485 | 0.85 | CHEK1 (0.63) | CHEK1RETTRPA1MAPK1PIK3CD | |
| SCHEMBL5805420 | 0.72 | RET (0.43) | CHEK1RETPIK3CDPIK3CAPIK3CB | |
| SCHEMBL30052782 | 0.71 | RET (0.42) | CHEK1RETTRPA1LRRK2PI4KA | |
| SCHEMBL22912722 | 0.71 | CHEK1 (0.66) | CHEK1TRPA1MAPK1LRRK2NOTUM | |
| SCHEMBL6531144 | 0.71 | RET (0.42) | CHEK1RETTRPA1LRRK2PI4KA | |
| SCHEMBL23735452 | 0.69 | CHEK1 (0.48) | CHEK1RETTRPA1LRRK2PI4KA | |
| SCHEMBL10259826 | 0.69 | AKT1 (0.45) | CHEK1RETTRPA1PIK3CDPIK3CA | |
| SCHEMBL868756 | 0.69 | RET (0.41) | CHEK1RETMAPK1LRRK2PI4KA | |
| SCHEMBL25776394 | 0.69 | TRPA1 (0.51) | CHEK1RETTRPA1JAK2 | |
| SCHEMBL19743349 | 0.69 | CHEK1 (0.41) | CHEK1RETTRPA1PIK3CDPIK3CA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 43 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250325550-A1 | HETEROCYCLYLAMINES AS PI3K INHIBITORS | INCYTE CORP (US) | 2025-10-23 | — | — | US | disclosed |
| EP-3888657-B1 | HETEROCYCLYLAMINES AS PI3K INHIBITORS | INCYTE HOLDINGS CORP (US) | 2025-03-19 | — | — | EP | disclosed |
| US-12201636-B2 | Heterocyclylamines as PI3K inhibitors | INCYTE CORPORATION (US) | 2025-01-21 | — | — | US | disclosed |
| US-20240216377-A1 | HETEROCYCLYLAMINES AS PI3K INHIBITORS | INCYTE CORPORATION | 2024-07-04 | — | — | US | disclosed |
| US-20240216377-A1 | HETEROCYCLYLAMINES AS PI3K INHIBITORS | INCYTE CORPORATION | 2024-07-04 | — | — | US | disclosed |
| US-11819505-B2 | Heterocyclylamines as PI3K inhibitors | INCYTE CORPORATION (US) | 2023-11-21 | — | — | US | disclosed |
| US-11819505-B2 | Heterocyclylamines as PI3K inhibitors | INCYTE CORPORATION (US) | 2023-11-21 | — | — | US | disclosed |
| US-20230121440-A1 | HETEROCYCLYLAMINES AS PI3K INHIBITORS | INCYTE HOLDINGS CORPORATION | 2023-04-20 | — | — | US | disclosed |
| US-20230121440-A1 | HETEROCYCLYLAMINES AS PI3K INHIBITORS | INCYTE HOLDINGS CORPORATION | 2023-04-20 | — | — | US | disclosed |
| US-11433071-B2 | Heterocyclylamines as PI3K inhibitors | INCYTE CORPORATION (US) | 2022-09-06 | — | — | US | disclosed |
| US-9707233-B2 | Heterocyclylamines as PI3K inhibitors | INCYTE HOLDINGS CORPORATION (US) | 2017-07-18 | — | — | US | disclosed |
| EP-2751109-B1 | HETEROCYCLYLAMINES AS PI3K INHIBITORS | INCYTE HOLDINGS CORP (US) | 2016-11-30 | — | — | EP | disclosed |
| US-9309251-B2 | Bicyclic azaheterocyclobenzylamines as PI3K inhibitors | INCYTE HOLDINGS CORPORATION (US) | 2016-04-12 | — | — | US | disclosed |
| US-20160024117-A1 | HETEROCYCLYLAMINES AS PI3K INHIBITORS | INCYTE CORPORATION | 2016-01-28 | — | — | US | disclosed |
| US-20160022685-A1 | HETEROCYCLYLAMINES AS PI3K INHIBITORS | INCYTE CORPORATION | 2016-01-28 | — | — | US | disclosed |
| US-9199982-B2 | Heterocyclylamines as PI3K inhibitors | INCYTE HOLDINGS CORPORATION (US) | 2015-12-01 | — | — | US | disclosed |
| EP-2751109-A1 | HETEROCYCLYLAMINES AS PI3K INHIBITORS | Incyte Corporation (US) | 2014-07-09 | — | — | EP | disclosed |
| US-20130261101-A1 | BICYCLIC AZAHETEROCYCLOBENZYLAMINES AS PI3K INHIBITORS | INCYTE CORPORATION | 2013-10-03 | — | — | US | disclosed |
| WO-2013033569-A1 | HETEROCYCLYLAMINES AS PI3K INHIBITORS | INCYTE CORPORATION (US) | 2013-03-07 | — | — | WO | disclosed |
| US-20130059835-A1 | HETEROCYCLYLAMINES AS PI3K INHIBITORS | INCYTE CORPORATION (US) | 2013-03-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230121440-A1 | HETEROCYCLYLAMINES AS PI3K INHIBITORS | PIK3CA, PIK3CD, PIK3CB | CHEK1 221/4885RET 994/4885TRPA1 2943/4885 |
| US-20250325550-A1 | HETEROCYCLYLAMINES AS PI3K INHIBITORS | PIK3CA, PIK3CD, PIK3CB | CHEK1 221/4885RET 994/4885TRPA1 2943/4885 |
| US-20240216377-A1 | HETEROCYCLYLAMINES AS PI3K INHIBITORS | PIK3CA, PIK3CD, PIK3CB | CHEK1 221/4885RET 994/4885TRPA1 2943/4885 |
| US-20160024117-A1 | HETEROCYCLYLAMINES AS PI3K INHIBITORS | PIK3CA, PIK3CD, PIK3CB | CHEK1 221/4885RET 994/4885TRPA1 2943/4885 |
| US-11819505-B2 | Heterocyclylamines as PI3K inhibitors | PIK3CA, PIK3CD, PIK3CB | CHEK1 221/4885RET 994/4885TRPA1 2943/4885 |
| US-11433071-B2 | Heterocyclylamines as PI3K inhibitors | PIK3CA, PIK3CD, PIK3CB | CHEK1 221/4885RET 994/4885TRPA1 2943/4885 |
| US-20160022685-A1 | HETEROCYCLYLAMINES AS PI3K INHIBITORS | PIK3CA, PIK3CD, PIK3CB | CHEK1 221/4885RET 994/4885TRPA1 2943/4885 |
| US-12201636-B2 | Heterocyclylamines as PI3K inhibitors | PIK3CA, PIK3CD, PIK3CB | CHEK1 221/4885RET 994/4885TRPA1 2943/4885 |
| US-20130261101-A1 | BICYCLIC AZAHETEROCYCLOBENZYLAMINES AS PI3K INHIBITORS | PIK3CD, PIK3CA, PIK3CB | CHEK1 783/4885RET 882/4885TRPA1 4207/4885 |
| US-20130059835-A1 | HETEROCYCLYLAMINES AS PI3K INHIBITORS | PIK3CA, PIK3CD, PIK3CB | CHEK1 221/4885RET 994/4885TRPA1 2943/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.